CD4 and metastatic melanoma: For example, a case study demonstrated that treatment with HLA-DP4-restricted NY-ESO-1 transduced CD4+ T cells can induce complete regression of a refractory metastatic melanoma, with a durable response ongoing at 22 months (109).